Antagonism of cannabinoid type 1 receptor (CB1R) reduced intestinal inflammation and permeability in a diet-induced obesity model, attenuating metabolic endotoxemia and adipose inflammation and improving insulin resistance [103]. Here, CNR1 is linked to obesity disorder.